ProCE Banner Series

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

Register now for this case-based workshop series on managing AML in older patients with AML and those with FLT3- or IDH1/2-mutated AML, including a discussion on managing key adverse events associated with targeted therapy.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for hematologists, oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with AML.

All Events

Past Events

July

31

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Host Group AL, Mobile, Alabama

August

19

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

1:00 PM - 2:00 PM Eastern Time (ET)

In-personVirtual

Private Event | Host Group at Hilton, Daytona Beach, Florida

August

22

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team [Open Registration]

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group VT, Bennington, Vermont

August

22

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event | Host Group MI, Royal Oak, Michigan

September

16

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

12:45 PM - 1:45 PM Central Time (CT)

In-person

Private Event | Host Group at III, Houston, Texas

October

11

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event, San Antonio, Texas

October

21

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

8:15 AM - 9:15 AM Pacific Time (PT)

In-person

Private Event | Host Group at III, Reno, Nevada

October

26

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team [Open Registration]

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

CCO Simulcast | Host Group ID, Post Falls, Idaho

November

06

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Dallas, Texas

November

06

2023

Individualized Management of AML: Guidance for the Community Multidisciplinary Team

7:00 PM - 8:00 PM Pacific Time (PT)

In-person

Private Event | Host Group Ming Yuan, Daly City, California

Faculty

ProCE Banner Faculty
Uma Borate, MD, MS

Clinical Associate Professor
Division of Hematology
Ohio State University, James Cancer Hospital
Columbus, Ohio

ProCE Banner Faculty
Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

ProCE Banner Faculty
Brian A. Jonas, MD, PhD, FACP

Professor of Medicine
Division of Malignant Hematology/Cellular Therapy and Transplantation
University of California Davis School of Medicine
Sacramento, California

ProCE Banner Faculty
Curtis Lachowiez, MD

Assistant Professor
Division of Hematology/Medical Oncology
Knight Cancer Institute, Oregon Health & Science University 
Portland, Oregon 

ProCE Banner Faculty
Catherine Lai, MD, MPH

Associate Professor 
Physician Leader 
Leukemia Clinical Research Unit
University of Pennsylvania’s Perelman Center for Advanced Medicine

ProCE Banner Faculty
Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Topics

Welcome & Demographic Polling

Discussion 1:  Older Patient with Newly Diagnosed AML Who is Ineligible for Intensive Induction Chemotherapy

  • Therapeutic options based on patient fitness and cytogenetic factors 

Discussion 2: Exploring AML Cases With Mutant IDH1/IDH2

  • Selective inhibitors of mutant IDH1/2
  • Managing treatment-related AEs associated with IDH inhibitors

Discussion 3: Newly Diagnosed FLT3-ITD Mutated AML

  • Clinical trial data on approved and investigational FLT3 inhibitors 
  • Managing treatment-related AEs associated with FLT3 inhibitors

Audience Question & Answer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of community multidisciplinary teams in integrating the available clinical data, guidelines, and expert recommendations into the care of their patients with AML.

Target Audience
This program is intended for hematologists, oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with AML. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Develop genetic testing strategies that incorporate best communication techniques and expert guidance for all patient subgroups with AML that may benefit from targeted therapy
  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Plan individualized AML therapeutic strategies considering the molecular profile along with available clinical evidence on efficacy and potential toxicities
  • Implement plans to educate patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-127-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AbbVie Inc. and Daiichi Sankyo, Inc.